Current Recruiting Clinical Trials
If you wish to participate in a clinical trial, speak with your treating oncologist or GP to see if there are current trials you may be suitable for.
If you cannot find a suitable trial under your specific cancer type, please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.
- TRIAL REFERENCE: LH19.060 PROOF QBGJ398-301
SUMMARY: A Phase 3 open label randomised, controlled study of oral infigratinib versus gemcitabine with cisplatin in subjects with advanced/metastatic or ineroperable cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF Trial
LEAD INVESTIGATOR:Dr Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.009 NUCANA NU TIDE 121
SUMMARY: A Phase 3 open label multi centre randomised study comparing NUC-1031 plus Cisplatin to Gemcitibine plus Cisplatin in patients with previously untreated locally advanced or metastatic Biliary Tract Cancer
LEAD INVESTIGATOR:Dr Hao-Wen Sim
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH16.037 PCR-MIB
SUMMARY: Clinical Study No. [ANZUP 1502], Phase II study of Pembrolizumab with ChemoRadiotherapy as treatment for muscle invasive bladder cancer protocol
LEAD INVESTIGATOR: A/Prof Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.040 THOR
SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
LEAD INVESTIGATOR: A/Prof Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.058 CA209-7G8
SUMMARY: A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination with Intravesical BCG versus Standard of Care BCG Alone in Participants with High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment with BCG
LEAD INVESTIGATOR:Dr Alison Zhang
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.062 CA209-9UT
SUMMARY: A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
LEAD INVESTIGATOR:Dr Alison Zhang
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.041 TROG 15.02 ROAM
SUMMARY: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (ROAM)
LEAD INVESTIGATOR:Dr Nitya Patanjali
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.003 NUTMEG
SUMMARY: A Randomised Phase II Study of NivIUmab and TeMozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG)
LEAD INVESTIGATOR: Prof John Simes
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.037 MoST Addendum 8-Substudies 19-20
SUMMARY: Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2
amplifications or mutations
LEAD INVESTIGATOR: Dr Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.029 WinPro
SUMMARY: An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
LEAD INVESTIGATOR: Dr Mun Hui
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.009 MK3475-756
SUMMARY: A Randomised, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Rick Early Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (Keynote 756
LEAD INVESTIGATOR: Dr Jane Beith
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.005 WO39391 BIG 16-AFT-27 IMPAssion
SUMMARY: A Phase 3 multicenter randomised open label study comparing atezolizuzmab (anti PDL1 antibody) in combination with adjuvant anthracycline /taxane based chemotherapy versus chemotherapy alone in patients with operable triple negative breast cancer
LEAD INVESTIGATOR: Dr Jane Beith
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.026 MK3475-630
SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
LEAD INVESTIGATOR: Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.062 CERPASS REPLIMUNE RPL-002
SUMMARY: A randomised controlled open label Phase 2 study of cemiplimab as a single agent & in combination with RP1 in patients with Advanced Cutaneous Squamous Cell Carcinoma
LEAD INVESTIGATOR: Dr Jenny Lee
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH16.050 CANNABIS
SUMMARY: CTC0146 : Pilot and definitive randomised double-blind, placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (The CannabisCINV study)
LEAD INVESTIGATOR: Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH15.055 AG0213CR ASCOLT
SUMMARY: AG0213CR : Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre Double Blind, Randomised Placebo Controlled Phase III Trial
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.027 SPAR
SUMMARY: A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.010 CSP ISO CC007 ISOFOL
SUMMARY: A randomised multi centrer parallel group Phase 3 study to compare the efficacy of arfolitixorin versus leucovorin incombination with 5-fluorouracil oxaliplatin and bevacizumab in patients with advanced colorectal cancer
LEAD INVESTIGATOR: Dr Kate Mahon
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH13.015 AG0407GR
SUMMARY:A randomised phase II/III trial of operative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer ( TOP GEAR : Trial Of Posteoperative therapy for Gastric and Esophagogastic junction AdenocaRcinoma)
LEAD INVESTIGATOR:Dr Regina Tse
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.040 THOR
SUMMARY: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations.
LEAD INVESTIGATOR: A/Prof Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.016 INOVATe
SUMMARY: Individualised Ovarian Cancer treatment through Integration of Genomic Pathology into Multidisciplinary Care.
Intensive molecular testing on primary tumours, samples collected at relapse (ascites and biopsies) and circulating tumour DNA. Genomic biomarkers to predict treatment response will be assessed and molecular testing will be used to assist in the selection of patients for clinical trials of targeted agents. Patients will be separately consented for any HREC-approved trial for which they are found to be eligible.
LEAD INVESTIGATOR: Dr Philip Beale
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.010 SOLACE 2
SUMMARY: A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects” SOLACE 2
LEAD INVESTIGATOR: Dr Philip Beale
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.040 MK7902-001
SUMMARY: A Phase 3 randomised, open label study of pembrolizumab (MK3475) plus lenvatinib (E7080/MK-7902) versus chemotherapy for first line treatment of advansed or recurrent Endometrial Carcinoma (LEAP-001)
LEAD INVESTIGATOR: Dr Michelle Harrison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH14.021 ANZUP 1302
SUMMARY: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk metastatic germ cell tumours (P3BEP Trial)
LEAD INVESTIGATOR: A/Prof Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.021 TIGER
SUMMARY: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
LEAD INVESTIGATOR: A/Prof Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH14.014 Prime Meso
SUMMARY: The identification of predictive and prognostic factors in malignant pleural mesothelioma and prognostic factors undergoing chemotherapy
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.019 ENRICH
SUMMARY: Embedding Research (and Evidence) in Cancer Healthcare (EnRICH)
LEAD INVESTIGATOR: Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.058 AMG 757
SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
LEAD INVESTIGATOR: Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.060 MK 3475-598
SUMMARY: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
LEAD INVESTIGATOR: Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.024 MK3475-789
SUMMARY: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
LEAD INVESTIGATOR: Prof Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.025 BO40336 (ALINA)
SUMMARY: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.017 61186372EDI1001
SUMMARY: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Anitbody, in Subjects with Advanced Non-Small Cell Lung Cancer
LEAD INVESTIGATOR: Prof Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.039 MK7902-006-01 (E7080-G000-315)
SUMMARY: A Phase 3 randomised, placebo controlled study to evaluate the safety and efficacy of pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK3475) with or without Lenvatinib (E74080/MK7902) as First-line intervantion in participants with metastatic nonsquamous non-small cell lung cancer (LEAP-006)
LEAD INVESTIGATOR:Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.055 CA207-77T
SUMMARY: A phase 3 randomised, double-blind study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical resection and adjuvant treatment with nivolumab or placebo for participants with resectable stage II-IIIB Non small cell lung cancer
LEAD INVESTIGATOR:Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.056 rAD-IFN-MM-301 INFINITE
SUMMARY: A Phase 3 open label randomised parallel group study to evaluate the efficacy & safety of intrapleural administration of Adenovirus-delivered Interferon Alpha-2b (rAD-IFN) in combination with Celecoxib & gemcitabine in Patients with malignant Pleural Mesothelioma
LEAD INVESTIGATOR:Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.061 D4194R00005
SUMMARY: PACIFIC Real World: First retrospective real-world data on unresectable stage III NSCLC Patients treated with durvalumab after chemoradiotherapy
LEAD INVESTIGATOR:Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.019 LIBRETTO 431 LOXO-292 J2G-MC-JZJC
SUMMARY: A multicentre randomised open label phase 3 trial comparing LOXO 292 to platinum based pemetrexed therapy with or without pembrolizumab as initial treatment of advanced metastatic RET fusion positive non small cell lung cancer
LEAD INVESTIGATOR:Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.021 AMG 510 CodeBreak 200
SUMMARY: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously
Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
LEAD INVESTIGATOR:Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.022 GO41767 SKYSCRAPER-02
SUMMARY: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Carboplatin And Etoposide With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Untreated Extensive-Stage Small Cell Lung Cancer.
LEAD INVESTIGATOR:Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.023 AMG 510 BIO MARKER – 20190294
SUMMARY: AMG510 A Non-Interventional Biomarker Study on the Molecular Evaluation of Archival Tumour Tissue in subjects with Non-Small Cell Lung Cancer.
LEAD INVESTIGATOR:Dr Michael Boyer
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.051
SUMMARY: 1336.11_An open label phase Ib dose finding study of BI 836880 in combination with BI754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
LEAD INVESTIGATOR:Dr Hao-wen SIm
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.052 FLAURA 2
SUMMARY: A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
LEAD INVESTIGATOR:Dr Hao-wen Sim
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.064 MeRmaiD-1 D910LC00001
SUMMARY: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)’
LEAD INVESTIGATOR:Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.091 B8011011 Umbrella Study of Sasanlimab in Participants with NSCLC
SUMMARY: A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
LEAD INVESTIGATOR:Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.030 MASTERPLAN
SUMMARY: MASTERPLAN: A randomized phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
LEAD INVESTIGATOR: Dr Leily Grezaei
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.031 LEEP
SUMMARY: A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.005 AMG 160
SUMMARY: A Phase 1 Study evaluating the Safety ,Tolerability, Pharmacokinteics and Efficacy of Prostate Specific Membrane Antigen Half-Lie Extended Bispecific T-cell Engager AMG 160 in subjects with metastatic Castration-resistant Prostate Canver
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.022 C3441021
SUMMARY: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Repair Deficiencies
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.037 PRINCE
SUMMARY: Phase Ib/II study of radionuclide 177 Lutetium-PSMA 617 Therapy in combination with pembrolizumab for Treatment of metastatic resisrtant Prostate Cancer (mCRPC)
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.063 AMG 509 20180146
SUMMARY: A Phase 1 study evaluating the safety , Tolerability, pharmacokinetics and efficacy of AMG 509 in subjects with metastatic Castration-resistant prostate cancers
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.025 MK3475-991-001
SUMMARY: Phase 3, Randomized, Double-blind Trial of Pembrolizumab Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.069 AMG 256
SUMMARY: AMG 256_A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
LEAD INVESTIGATOR:Dr Mun Hui
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.045 CA209-933ISR
SUMMARY: Nivolumab in renal transplant recipients with poor prognosis cancers – a safety study.
LEAD INVESTIGATOR: Prof Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH16.038 EZH-202
SUMMARY: Clinical Study No. EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
LEAD INVESTIGATOR: David Thomas
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.037 MOST Sub Study 10
SUMMARY: Single arm, open label, singal seeking, phase Iia trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.33
LEAD INVESTIGATOR: Dr Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.023 SU2C-SARC-032
SUMMARY: SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
LEAD INVESTIGATOR: A/Prof Angela Hong
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.019 rECCUr
SUMMARY: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
LEAD INVESTIGATOR: Dr Vivek Bhadri
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.016 CAMPRIRE JAAA
SUMMARY: CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
LEAD INVESTIGATOR: Dr Vivek Bhadri
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.032 E7080-G000-230 OLIE
SUMMARY: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)
LEAD INVESTIGATOR: Dr Vivek Bhadri
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH16.005 MK-3475-158
SUMMARY: Clinical Study No. MK-3475-158 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
LEAD INVESTIGATOR: Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.037 MOST Sub Study 9 – PTCH1 or SMO mutations
SUMMARY: Single arm, open label, signal seeking phase Iia trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations
LEAD INVESTIGATOR: DR Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.053 MK7684-001
SUMMARY: A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours
LEAD INVESTIGATOR: Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.058 AMG 757
SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
LEAD INVESTIGATOR: Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.021 TIGER TICE
SUMMARY: A randomised Phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide & cisplatin (TIP) with high dose chemptherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin & etoposide (TI-CE) as first salvage treatment in relapsed or refactory germ cell tumors
LEAD INVESTIGATOR: Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.045 CA209-933 ISR – CALHAN
SUMMARY: PD-1 blockade in renal transplant patients with poor prognosis cancer and minimising risk organ rejection using comprehensive immune monitoring and screening techniques as a safetystudy – SHORT TITLE – Nivolumab inrenal transplant recipients with cancer
LEAD INVESTIGATOR: Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.004 FPT155-001
SUMMARY: A Phase 1a/1b Study of FPT155 in patients with advanced Solid Tumors
LEAD INVESTIGATOR: Dr Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.005 AMG 160
SUMMARY: A Phase 1 Study evaluating the Safety ,Tolerability, Pharmacokinteics and Efficacy of Prostate Specific Membrane Antigen Half-Lie Extended Bispecific T-cell Engager AMG 160 in subjects with metastatic Castration-resistant Prostate Canver
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.008 MK3475-587
SUMMARY: A Multi-center, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
LEAD INVESTIGATOR: Dr Catriona McNeil
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.014 CPI-006-01
SUMMARY: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CP-I006. As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
LEAD INVESTIGATOR: Dr Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.017 61186372EDI1001
SUMMARY: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Anitbody, in Subjects with Advanced Non-Small Cell Lung Cancer
LEAD INVESTIGATOR: Prof Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.018 PSI 617-101
SUMMARY: Phase 1b/2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer’
LEAD INVESTIGATOR: Dr Mun Hui
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria.
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.024 AMG 404
SUMMARY: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients with Advanced Solid Tumors’
LEAD INVESTIGATOR: Dr Mun Hui
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.026 MK3475-630
SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
LEAD INVESTIGATOR: Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.037 PRINCE
SUMMARY: Phase Ib/II study of radionuclide 177 Lutetium-PSMA 617 Therapy in combination with pembrolizumab for Treatment of metastatic resisrtant Prostate Cancer (mCRPC)
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.045 TKI- TPX-005 (TRIDENT-1)
SUMMARY: A Phase 1/2 open label multi centre first in human study of the safety, tolerability, pharmacokinetics and anti tumour activity of TPX-005 in patients with advanced solid tumours harbouring ALK, ROS1 or NTRK1-3 rearrangments TRIDENT-1
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.048 MG010 Metagone SUCCEED
SUMMARY: A Phase I/II open label multi-centre study to assess the safety tolerability and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.049 BGB-900-105
SUMMARY: Phase 1/1b investigating tolerability, pharmacokinetics & preliminary Antitumour Activity of Anti TIGIT Monoclonal Antibody Tislelizumab (BGB-A317) in patients with unresectable Locally Advanced or metastatic solid tumours
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.057 CC95251 SIRPa
SUMMARY: Phase 1 open label dose finding study of CC-95251, a monoclonal antibody directed against SIRPa Alone and in combination with cetuximab in subjects with advanced solid and hematologic cancers
LEAD INVESTIGATOR: Dr Lisa Hovarth
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.062 CERPASS
SUMMARY: A randomised controlled open label Phase 2 study of cemiplimab as a single agent & in combination with RP1 in patients with Advanced Cutaneous Squamous Cell Carcinoma
LEAD INVESTIGATOR: DR Jenny Lee
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.063 AMG 509 20180146
SUMMARY: A Phase 1 study evaluating the safety , Tolerability, pharmacokinetics and efficacy of AMG 509 in subjects with metastatic Castration-resistant prostate cancers
LEAD INVESTIGATOR: Prof Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.003 LIBRETTO 201 LOXO RET
SUMMARY: A multicenter expanded access program (EAP) for the treatment of patients with locally advanced or metastatic solid tumours with rearranged transfection (RET) Activation LOBRETTO 201
LEAD INVESTIGATOR: Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.012 RAGNAR
SUMMARY: A Phase 2 study of Erdafitinib in subjects with advanced solid tumours and EGFR Gene Alterations
LEAD INVESTIGATOR: Dr Alison Zhang
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.013 M19-345 ABBV-151
SUMMARY: A Phase 1 first in human multi centre open label dose escalation study to determine the safety tolerability pharmacokinetics and RP2D of ABBV-151 as a single agent and in combination with ABBV-181 in subjects with locally advanced or metastatic solid tumours
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.014 SQ3370
SUMMARY: A Multicentre Phase 1 open label study of SQ3370 inpatients with advanced solid tumours
LEAD INVESTIGATOR: Dr Vivek Bhadri
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.016 CAMPRIRE JAAA
SUMMARY: CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
LEAD INVESTIGATOR: Dr Vivek Bhadri
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.039 XL184-021
SUMMARY: XL184 A Phase 1B Dose Escalation study of Cabozantinib administered alone or in combination with Atezolizumab to subjects with loally advanced or metastatic solid tumours
LEAD INVESTIGATOR: Dr Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.051
SUMMARY: 1336.11_An open label phase Ib dose finding study of BI 836880 in combination with BI754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
LEAD INVESTIGATOR:Dr Hao-wen SIm
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.057 C0541001
SUMMARY: A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS
LEAD INVESTIGATOR: Dr Mun Hui
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.059 CA209-8TT
SUMMARY: Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
LEAD INVESTIGATOR: Dr Catriona McNeil
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.091 B8011011 Umbrella Study of Sasanlimab in Participants with NSCLC
SUMMARY:A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
LEAD INVESTIGATOR:Dr Michael Boyer
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.040 THOR – JNJ 42756493
SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
LEAD INVESTIGATOR: Professor Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH14.014 Prime Meso
SUMMARY: The identification of predictive and prognostic factors in malignant pleural mesothelioma and prognostic factors undergoing chemotherapy
LEAD INVESTIGATOR: Dr Steven Kao
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.037 MOST Sub Study 9 – PTCH1 or SMO mutations
SUMMARY: Single arm, open label, signal seeking phase Iia trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations
LEAD INVESTIGATOR: DR Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH17.037 MOST Sub Study 10
SUMMARY: Single arm, open label, singal seeking, phase Iia trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.33
LEAD INVESTIGATOR: DR Peter Grimison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.003 NUTMEG
SUMMARY: A Randomised Phase II Study of NivIUmab and TeMozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG)
LEAD INVESTIGATOR: Dr John Simes
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH18.041 TROG 15.02 ROAM
SUMMARY: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled tiral (ROAM)
LEAD INVESTIGATOR: Dr Nitya Patanjali
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.006 WEHI
SUMMARY: The WEHI Stafford Rare Cancer Program – Discovery of novel therapeutic targets within the biology of rare cancers
LEAD INVESTIGATOR: DR Michelle Harrison
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH19.014 CPI-006-01
SUMMARY: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CP-I006. As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
LEAD INVESTIGATOR: Dr Lisa Horvath
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here
- TRIAL REFERENCE: LH20.011 CARE
SUMMARY: Cannabinoids for symptomcontrol in advanced cancer, open label prospective clinical trials in NSW
LEAD INVESTIGATOR: Dr Judith Lacey
ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
REFER A PATIENT: Click here